SCHEDULE: Perceptive Advisors Discloses 7.3% Stake in X4 Pharma

Perceptive Advisors LLC and Joseph Edelman have reported a 7.3% beneficial ownership stake in X4 Pharmaceuticals, Inc. via a Schedule 13G filing.

Summary

• Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. collectively report beneficial ownership of 6,889,163 shares of X4 Pharmaceuticals, Inc. common stock.
• The reported stake represents 7.3% of the company's outstanding common stock, based on 94,319,696 shares outstanding as of May 1, 2026.
• The holdings consist of 6,737,648 shares of common stock and 151,515 warrants that are currently exercisable.
• The reporting persons maintain shared voting and dispositive power over the entire position.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive development, as it confirms stable institutional interest without indicating any immediate strategic shifts or corporate distress.

Positives

• Institutional backing from a specialized life sciences investment firm suggests confidence in the company's long-term prospects.
• The investment is structured as a passive holding, indicating no immediate intent to disrupt corporate control.

Negatives

• The inclusion of warrants in the beneficial ownership calculation is subject to a 9.99% beneficial ownership limitation, which caps immediate conversion potential.

Risks

• The investment is subject to market volatility inherent in the biotechnology sector.
• Future dilution of equity could impact the percentage of ownership held by the reporting persons.

Future Outlook

The filing does not provide specific forward-looking guidance regarding the issuer's business operations, as it is a disclosure of beneficial ownership.

Industry Context

StockSavvy.ai notes that Perceptive Advisors is a prominent life sciences investor; their continued interest in X4 Pharmaceuticals signals ongoing institutional support for the company's clinical development pipeline within the competitive rare disease space.

Comparison to Industry Standards

• The 7.3% stake is consistent with typical institutional position sizing for small-cap biotechnology firms.
• The use of a 9.99% beneficial ownership limitation on warrants is a standard protective measure in institutional biotech investment agreements.

Stakeholder Impact

• Shareholders may view the continued presence of a major life sciences investor as a vote of confidence in the company's clinical progress.

Next Steps

• The reporting persons will continue to monitor their investment in X4 Pharmaceuticals.

Key Dates

Keywords

X4 Pharmaceuticals, Perceptive Advisors, Schedule 13G, Biotechnology, Institutional Ownership, Joseph Edelman